Opinion|Videos|December 10, 2024
Insights on Managing Cough Symptoms in Patients With IPF
Author(s)Steven D. Nathan, MD
Key Takeaways
- Current IPF cough treatments are often inadequate, highlighting the need for improved therapeutic strategies and a deeper understanding of underlying mechanisms.
- The study identifies potential pathways for novel interventions, which could significantly enhance patient quality of life by targeting specific mechanisms.
Steven Nathan, MD, discusses how the findings from the study on oral nalbuphine extended release suggest that this treatment may offer an effective option for managing IPF-related cough, providing significant relief in terms of both frequency and severity, which could shift current management strategies by introducing a more targeted, pharmacologic approach to addressing one of the most challenging symptoms of IPF.
Advertisement
Episodes in this series
- What are your key takeaways from this study, and how might these findings impact the way IPF cough symptoms are currently managed?
Advertisement
Related to this article
FDA approved belzutifan plus lenvatinib for advanced ccRCC after PD-1/PD-L1 therapy, expanding treatment options for those with disease progression.
A 3-year registry found dupilumab controlled atopic dermatitis (AD) in most children, though those under 6 years were likelier to stop treatment.
Machine learning identified age, BMI, income, and reproductive factors as key predictors of overactive bladder risk among US women.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Boarding admitted patients on inpatient floor hallways can alleviate emergency department (ED) crowding. Outcomes tend to be positive, but the published evidence is weak, according to this systematic review.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Most community oncology practices now administer bispecific antibodies in-office, but reimbursement gaps remain a top barrier, a survey finds.
Tammy Lundstrom, MD, JD, discusses the new childhood vaccine order, single-dose MMR access concerns, and the measles resurgence.
Advertisement
Advertisement
Trending on AJMC
1
Perceptions About CGMs Among Primary Care Physicians and Endocrinologists
2
COVID-19 or Flu? Symptoms Alone Can't Tell: Tammy Lundstrom, MD, JD
3
Surrogate End Points, Drug Costs Complicate Oncology Formularies
4
Oncology Patients in Clinical Trials: A Health Care Cost Analysis
5